ATE403665T1 - Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1 - Google Patents

Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1

Info

Publication number
ATE403665T1
ATE403665T1 AT02720906T AT02720906T ATE403665T1 AT E403665 T1 ATE403665 T1 AT E403665T1 AT 02720906 T AT02720906 T AT 02720906T AT 02720906 T AT02720906 T AT 02720906T AT E403665 T1 ATE403665 T1 AT E403665T1
Authority
AT
Austria
Prior art keywords
pgc
methods
gluconeogenesis
compositions
modulating
Prior art date
Application number
AT02720906T
Other languages
English (en)
Inventor
Bruce Spiegelman
Clifford Yoon
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE403665T1 publication Critical patent/ATE403665T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02720906T 2001-02-05 2002-02-05 Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1 ATE403665T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26676501P 2001-02-05 2001-02-05

Publications (1)

Publication Number Publication Date
ATE403665T1 true ATE403665T1 (de) 2008-08-15

Family

ID=23015907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720906T ATE403665T1 (de) 2001-02-05 2002-02-05 Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1

Country Status (8)

Country Link
US (3) US20030045470A1 (de)
EP (1) EP1366059B1 (de)
JP (1) JP2004526436A (de)
AT (1) ATE403665T1 (de)
AU (1) AU2002251873A1 (de)
CA (1) CA2437727A1 (de)
DE (1) DE60228056D1 (de)
WO (1) WO2002062297A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579093A1 (en) 2004-09-03 2006-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating pgc-1.alpha. to treat neurological diseases and disorders
FI20041540A0 (fi) * 2004-11-29 2004-11-29 Markku Laakso Menetelmä diabetesta hoitavien yhdisteiden seulomiseksi
WO2007106488A2 (en) * 2006-03-13 2007-09-20 Wyeth Modulators of gluconeogenesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426411B1 (en) 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
US6166192A (en) * 1997-05-30 2000-12-26 Dana-Farber Cancer Institute PGC-1, a novel brown fat PPARγ coactivator

Also Published As

Publication number Publication date
DE60228056D1 (de) 2008-09-18
US20030045470A1 (en) 2003-03-06
EP1366059A2 (de) 2003-12-03
EP1366059B1 (de) 2008-08-06
US20050234001A1 (en) 2005-10-20
WO2002062297A2 (en) 2002-08-15
CA2437727A1 (en) 2002-08-15
AU2002251873A1 (en) 2002-08-19
US7371529B2 (en) 2008-05-13
JP2004526436A (ja) 2004-09-02
US20080248475A1 (en) 2008-10-09
EP1366059A4 (de) 2004-03-31
WO2002062297A9 (en) 2002-12-12
WO2002062297A3 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
MY146548A (en) Certain chemicals entities, compositions, and methods
DE602004022020D1 (de) Oligomere verbindungen zur modulation der expression von survivin
ATE437184T1 (de) Varianten der fc-region
DK2392564T3 (da) c-Met-modulatorer og anvendelsesfremgangsmåder
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
WO2007094755A3 (en) Compositions and methods for modulating cognitive function
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
ATE471722T1 (de) Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
ATE403665T1 (de) Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1
DE60140074D1 (de) Non-apoptotische formen des zelltods und verfahren zur modulation
DE69943374D1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
DE60325695D1 (de) Der eaat2-promotor und dessen verwendung
IL203968A0 (en) Photodamage modulator for treating uv photodamage
ATE351906T1 (de) Zur modulation der krebszellenproliferation geeignetes polynukleotid
GB0016362D0 (en) Tetraspanin modulation
DE69727529D1 (de) Benzothiophenverbindungen, Zwischenprodukte, Zusammensetzungen und Methode
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
WO2003064451A3 (en) MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
DE69711528D1 (de) Naphthofluorenverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties